Mhairi Copland, MB ChB, PhD, Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK, discusses the DESTINY trial (NCT01804985). This trial aimed to examine the effects of gradual treatment withdrawal and whether TFR is feasible for chronic myeloid leukemia (CML) patients with less deep but stable remission. This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
